Please assess the completion status of the following clinical trial:

Trial Title: Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis~* Starting or already being treated with standard dose adalimumab, 40 mg subcutaneously (SQ) every two weeks~* Good medication adherence rate defined as Proportion of Days Covered (PDC) 80% and above~Exclusion Criteria:~* Detectable anti-adalimumab antibodies~* Overlapping immune mediated diseases~* Steroid therapy for more than 2 months prior to study enrollment~* Poor medication adherence rate (PDC \< 80%)~* History of recurrent infection resulting in therapy pause~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TDM based adalimumab dose optimization group (Type: EXPERIMENTAL): Therapeutic drug monitoring (TDM) provides an opportunity for a proactive and individualized therapy optimization based on serum drug concentration and anti-drug antibodies development.
- Standard of care (Type: NO_INTERVENTION): Standard of care practice for RA management is based on disease activity guided therapy adjustments.

Based on this trial design, predict the completion outcome and termination type (if applicable).